<DOC>
	<DOCNO>NCT00892424</DOCNO>
	<brief_summary>Cancers spread liver primary cancer location ( liver metastasis ) remove surgically ( unresectable ) treat chemotherapy and/or radiation therapy . Previous research show tumour often abnormal blood vessel may reduce effect radiation therapy . New drug , know `` anti-angiogenic '' drug show animal human study damage change tumour blood vessel way may make tumor sensitive radiation treatment . 32- 44 Patients diagnose unresectable liver metastasis invite take part study . The purpose study investigate use new anti-angiogenic drug call Sorafenib , combination radiation therapy chemotherapy . The study test effective new treatment , side effect associate new treatment , help establish safe dosage study medication .</brief_summary>
	<brief_title>Sorafenib-RT Treatment Liver Metastasis ( SLIM )</brief_title>
	<detailed_description>In study , Stereotactic Body Radiation Therapy ( SBRT ) Whole Liver Radiotherapy ( WLRT ) use concurrently sorafenib 3 different dosage determine tolerability efficacy combine treatment . Sorafenib dose 200mg twice daily orally 28 day level I , 400 mg morning 200mg evening level II , 400mg twice daily orally 28 day level III . Radiotherapy start day 8 , patient receive total 6 fraction 2 week . Patients assessed weekly treatment , 1 month post-tx , 3-month interval year tx , followed-up 6-month interval 3 year . Once Maximum Tolerated Dose ( MTD ) establish , expand cohort stratum accrue total 10 patient per stratum . This allow u gain experience regimen consolidate safety efficacy data . Quality Life ( QOL ) assessment carry baseline 1/3/6/9 mos post-tx . Patients also offer correlative study look biomarkers tissue , blood , urine sample , image study look tissue perfusion .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically confirm liver metastases Largest burden disease hepatic 's extrahepatic disease exist Tumour medically inoperable Patient life expectancy least 3 month KPS performance status least 60 % . Patient 18 year age old Patient adequate organ function Patient Creatinine â‰¤ 2 time upper limit normal range Patient recover effect prior therapy Patient ( person represent patient ) able give inform consent Patient Child 's A score ( 5 6 ) score For woman childbearing age , birth control use pregnancy test negative No major surgery past 4 week . No previous use sorafenib previously . Patient receive systemic therapy investigational agent within 2 week radiotherapy No previous upper abdominal radiation therapy liver . No serious medical condition may aggravate treatment , include limited : myocardial infarction within 6 month , congestive cardiac failure , unstable angina , active cardiomyopathy , unstable ventricular arrhythmia , uncontrolled hypertension , uncontrolled psychotic disorder , serious infection , active peptic ulcer disease , active liver disease previous stroke . Patients infected human immunodeficiency virus ( HIV ) , receive combination antiretroviral therapy No clinically significant liver failure ( i.e . encephalopathy ascites find clinically ) . No thrombolytic therapy within 4 week receive anticoagulant therapy . No underlying cirrhosis Child 's B C score . No history uncontrolled , life threaten malignancy within past 6 month . Patient variceal bleed gastrointestinal bleed past 2 month . No brain metastases Patient pregnant . Patients Rifampin , St. John 's Wort , Phenytoin , Carbamazepine , Phenobarbital , Chronic use ( 4 week ) dexamethasone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Liver metastasis</keyword>
	<keyword>sorafenib</keyword>
	<keyword>Liver metastasis cancer</keyword>
</DOC>